Search results
Understanding the Beta Thalassemia Minor Trait
Verywell Health via Yahoo News· 8 months agoBeta thalassemia minor—also known as beta thalassemia trait or B thalassemia—is a blood disorder. It lowers your blood's level of hemoglobin, an...
Canadian TV host Keltie Knight had her uterus removed after 'stubborn' blood disorder. What is...
Yahoo Canada Style· 1 month agoThis article is for informational purposes only and is not a substitute for professional medical...
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
Motley Fool via Yahoo Finance· 4 months agoCRISPR Therapeutics (NASDAQ: CRSP) has climbed more than 60% this year -- and for good reason. The...
Dr. Jeff Hersh explains what causes anemia and options on how it can be treated
Gannett via AOL· 6 months agoQ: What causes anemia, and is a blood transfusion the only treatment? A: Red blood cells are a...
Here Are the New Drugs and Treatments We Could See in 2024
Time via Yahoo News· 4 months agoCredit - Getty Images 2023 was a strong year for innovative new drugs, with new medications for...
Pfizer to end license deal with Syros for blood disorder therapies
Reuters via Yahoo News· 9 months agoShares of Syros were down 5.7% in trading after the bell. The termination will end the company's...
Hemochromatosis (Iron Overload): What to Know
Verywell Health via Yahoo News· 2 months agoA condition that causes excess iron accumulation in the body Medically reviewed by Benjamin Leach, MD Hemochromatosis is a medical condition where people...
UPDATE 1-Vertex/CRISPR's gene editing therapy cost effective at $1.9 million - pricing review group
Reuters via Yahoo Finance· 1 year agoVertex Pharmaceuticals Inc and CRISPR Therapeutics AG's one-dose gene editing therapy for sickle...
These 2 Stocks Are Heading for a Big Moment. Time to Buy?
Motley Fool· 9 months agoVertex Pharmaceuticals (NASDAQ: VRTX) and CRISPR Therapeutics (NASDAQ: CRSP) both are approaching a...
Agios Pharma's blood disorder drug meets goals of late-stage study
Reuters via AOL· 4 months agoThe drug, mitapivat, met the main goal of the study as it showed a statistically significant increase in hemoglobin response compared with placebo in patients suffering from either alpha- or ...